A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Hyperoxaluria

Interventions

DRUG

Tenapanor

Each tablet 30 mg

OTHER

Placebo

Trial Locations (1)

RECRUITING

UT Southwestern Medical Center, Dallas

All Listed Sponsors

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

University of Texas Southwestern Medical Center

OTHER